A PRELIMINARY STUDY TO EVALUATE CYSTEAMINE THERAPY IN HUMAN SUBJECTS WITH NASH

评估半胱胺治疗纳什人类受试者的初步研究

• 批准号: 8166857
• 负责人: JOEL Edward LAVINE
• 金额: $ 1.83万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166857
• 关键词: Biological Markers; Computer Retrieval of Information on Scientific Projects Database; Cysteamine; Funding; Grant; Institution; Research; Research Personnel; Resources; Source; Steatohepatitis; United States National Institutes of Health; human subject

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in human subjects.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 确定半胱胺是否能有效降低或逆转人类受试者脂肪性肝炎的生物标志物。